We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: maintenance therapy
MedXY News
EnglishTag

maintenance therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma
Hematology-Oncologymaintenance therapysurvival outcomes

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma

By MedXY|Sep 22, 2026

Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.

Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma
DermatologyCutaneous T-Cell Lymphoma
maintenance therapy

Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma

By MedXY|Feb 17, 2026

The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study
Oncologymaintenance therapysmall-cell lung cancer

Safety and Activity of Tarlatamab Combined with PD-L1 Inhibitors as First-Line Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: Insights from the DeLLphi-303 Phase 1b Study

By MedXY|Oct 15, 2025

This review synthesizes evidence on tarlatamab plus PD-L1 inhibitors as maintenance therapy post chemo-immunotherapy in extensive-stage SCLC, highlighting safety, clinical activity, and translational implications from the DeLLphi-303 study

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
Clinical Updatesacute myeloid leukaemiahematopoietic stem-cell transplantation

Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS

By MedXY|Oct 9, 2025

A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu

Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial
Clinical Updatesacute myeloid leukemiahematopoietic stem-cell transplantation

Oral Decitabine and Cedazuridine as Maintenance Therapy Post-HSCT in Very High-Risk AML and MDS: Insights from the GFM-DACORAL-DLI Phase 2 Trial

By MedXY|Oct 9, 2025

A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Clinical Updatesmaintenance therapy

Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study

By MedXY|Oct 8, 2025

Maintenance therapy with romidepsin following autologous hematopoietic stem-cell transplantation (AHCT) in peripheral T-cell lymphoma (PTCL) demonstrated feasibility and an estimated 2-year progression-free survival (PFS) of 62%, though the

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial
newsDoxorubicinmaintenance therapy

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY|Oct 2, 2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safet

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial
Clinical Updatesatezolizumabimmunotherapy

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY|Oct 1, 2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure